THE MALE THERAPIST AND THE FEMALE ADOLESCENT PATIENT

1970 ◽  
Vol 9 (4) ◽  
pp. 707-721 ◽  
Author(s):  
Ake Mattsson
2020 ◽  
Vol 19 (4) ◽  
pp. 763-768
Author(s):  
Kamrun Nessa ◽  
Nabila Anwar ◽  
Ranjit Ghosh ◽  
Sonali Mondal ◽  
Mohammad Khursheed Alam

The decision forutilization of a space of a retained deciduous molar to alleviate crowding in late mixed dentition is one of the critical aspects in orthodontic treatment.Hence, the aimof the treatment hereis to use the extraction spaces properly to relieve severe crowding and align both the arches to the point where a stable overjet/overbite exist. This case report presenting a 13-year-old female adolescent with severe crowding in both upper and lower jaw and a convex profile. Although she was initially anxious to extract her teeth to treat her case but also she was looking for desirable results. The case was later treated in a conventional orthodontic approach with extraction ofthree 1stpremolars. It was quite challenging to make the best use of the space of missing lower right 2nd premolar after extraction of deciduous second molar on that sideto relieve severe crowding. However; at the end of the treatment, the patient expressed satisfaction with the results- proper bite, smile and most importantly esthetics. This case report demonstrates successful treatment of an adolescent patient with severe crowding by proper utilization of the extraction spaces. Bangladesh Journal of Medical Science Vol.19(4) 2020 p.763-768


2004 ◽  
Vol 171 (4S) ◽  
pp. 421-422
Author(s):  
Paul J. Russinko ◽  
Anthony A. Caldamone ◽  
Mark Sigman

Author(s):  
Frank Häßler ◽  
Olaf Reis ◽  
Steffen Weirich ◽  
Jacqueline Höppner ◽  
Birgit Pohl ◽  
...  

This article presents a case of a 14-year-old female twin with schizophrenia who developed severe catatonia following treatment with olanzapine. Under a combined treatment with amantadine, electroconvulsive therapy (ECT), and (currently) ziprasidone alone she improved markedly. Severity and course of catatonia including treatment response were evaluated with the Bush-Francis Catatonia Rating Scale (BFCRS). This case report emphasizes the benefit of ECT in the treatment of catatonic symptoms in an adolescent patient with schizophrenic illness.


2006 ◽  
Vol 37 (06) ◽  
Author(s):  
M Karenfort ◽  
M Heckel ◽  
B Assmann ◽  
D Tibussek ◽  
E Mayatepek

2020 ◽  
Vol 36 (2) ◽  
pp. 95-106
Author(s):  
Agnieszka M. Piróg-Balcerzak ◽  
Anna K. Bażyńska ◽  
Katarzyna Biernacka ◽  
Joanna Brągoszewska ◽  
Lidia Popek ◽  
...  

Objective. Omega–3 polyunsaturated fatty acids (PUFAs) were tested in adolescent depression and in several neurodevelopmental disorders with partial success. Anorexia nervosa (AN) is characterised by deficiencies in fatty food intake and frequent comorbidity, including depressive and cognitive symptoms. Thus supplementation with PUFAs may be beneficial in this group of patients. The aim of the study was to assess whether PUFAs as an add-on treatment is associated with better improvement of body mass index (BMI) and psychopathological symptoms than placebo in patients with AN. Method. 61 female adolescent inpatients with AN were randomly allocated to omega–3 PUFAs supplementation or placebo for 10 weeks. Patients also participated in the behavioural programme and eclectic psychotherapy (treatment as usual, TAU). At baseline and follow-up visits, patients’ BMI and psychopathology were assessed with Clinical Global Impression Scale (CGI), Patient Global Impression Scale (PGI), and Eating Attitude Test (EAT-26). Results. After 10 weeks, both groups showed improvement in all parameters. Improvement in CGI scores was observed greater in placebo vs. PUFA-s group (p = 0.015) while other differences were not statistically significant. Omega–3 PUFAs supplementation appears not to be effective as an add-on treatment in inpatient adolescent girls with anorexia nervosa. Conclusions. The results should be analysed with caution due to small sample size and heterogeneity in TAU. As the TAU turned out to be highly effective, additional therapeutic effect of PUFA might not be visible. Nevertheless, that does not explain the tendency for better improvement in the placebo group.


Sign in / Sign up

Export Citation Format

Share Document